A conjugate vaccine for Africa
MVP support has been critical to the development of a conjugate vaccine for meningitis A in Africa. |
Our client is the African child. He or she comes first. Always.
Because group A Neisseria meningitidis is the pathogen responsible for most epidemics in the meningitis belt, MVP has decided to develop a monovalent group A conjugate vaccine for Africa.
The meningococcal A conjugate vaccine has little commercial market outside of Africa. The development of this vaccine would not have been possible without the support of MVP. It is estimated that the project will need 250 million doses of the new conjugate A vaccine over 10 years to inoculate all individuals between 1 and 29 years of age in the meningitis belt.
Photo: Yvan Hutin.
